Press Releases

    • NOV 11 2020

    ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

    Philadelphia, PA (November 11, 2020) – Oncoceutics, Inc. announced that the latest research on imipridones ONC201 and ONC206 for the treatment of brain tumors will be presented at the 2020 Society of Neuro-Oncology Virtual Annual Meeting to be held November 19th-21st. These data will highlight clinical and translational findings over the past year, including: Updated

    • NOV 05 2020

    Oncoceutics Receives Foundation Grants to Establish an Expanded Access Program for ONC201

    Philadelphia, PA (November 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that it has received grants from Michael Mosier Defeat DIPG Foundation, Dragon Master Foundation and The ChadTough Foundation to fund an Expanded Access program for ONC201 in the United States. The program will allow Oncoceutics to work with physicians

    • OCT 28 2020

    Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH

    Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human clinical trial of the company’s next-generation imipridone ONC206 at the National Institutes of Health (“NIH”). The Phase I trial, for adults with recurrent primary central nervous system (CNS) neoplasms, is led by Mark Gilbert, MD,

    • OCT 12 2020

    Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212

    Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant for a Composition of Matter patent for ONC212, one of the company’s next-generation oncology drug candidates. The company also announced that a pending ONC201 patent has been granted for Mexico and that it received a